TWD 361.5
(-0.14%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.68 Billion TWD | 5.83% |
2022 | 1.5 Billion TWD | 0.48% |
2021 | 1.49 Billion TWD | 30.56% |
2020 | 1.14 Billion TWD | 26.89% |
2019 | 902.61 Million TWD | 11.23% |
2018 | 811.49 Million TWD | 17.13% |
2017 | 692.82 Million TWD | 14.84% |
2016 | 603.3 Million TWD | 13.26% |
2015 | 532.69 Million TWD | 39.06% |
2014 | 383.07 Million TWD | 35.42% |
2013 | 282.88 Million TWD | 98.86% |
2012 | 142.25 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 379.28 Million TWD | -16.61% |
2024 Q2 | 385.03 Million TWD | 1.52% |
2024 Q3 | 400.06 Million TWD | 3.9% |
2023 Q1 | 349.95 Million TWD | -13.63% |
2023 Q3 | 445.84 Million TWD | 16.59% |
2023 Q2 | 382.39 Million TWD | 9.27% |
2023 Q4 | 454.82 Million TWD | 2.01% |
2023 FY | 1.59 Billion TWD | 5.83% |
2022 Q4 | 405.18 Million TWD | 8.63% |
2022 Q2 | 350.41 Million TWD | -6.27% |
2022 FY | 1.5 Billion TWD | 0.48% |
2022 Q1 | 373.85 Million TWD | -7.49% |
2022 Q3 | 372.97 Million TWD | 6.44% |
2021 Q1 | 334.11 Million TWD | -15.26% |
2021 FY | 1.49 Billion TWD | 30.56% |
2021 Q4 | 404.11 Million TWD | 6.05% |
2021 Q3 | 381.04 Million TWD | 1.35% |
2021 Q2 | 375.98 Million TWD | 12.53% |
2020 Q2 | 240.67 Million TWD | 9.52% |
2020 FY | 1.14 Billion TWD | 26.89% |
2020 Q3 | 290.55 Million TWD | 20.73% |
2020 Q1 | 219.75 Million TWD | -17.22% |
2020 Q4 | 394.3 Million TWD | 35.71% |
2019 Q3 | 230.88 Million TWD | 18.88% |
2019 Q2 | 194.21 Million TWD | -8.41% |
2019 Q1 | 212.04 Million TWD | 0.15% |
2019 FY | 902.61 Million TWD | 11.23% |
2019 Q4 | 265.46 Million TWD | 14.98% |
2018 Q4 | 211.73 Million TWD | 3.13% |
2018 FY | 811.49 Million TWD | 17.13% |
2018 Q3 | 205.31 Million TWD | 4.19% |
2018 Q2 | 197.05 Million TWD | -0.37% |
2018 Q1 | 197.77 Million TWD | 9.75% |
2017 Q3 | 180.21 Million TWD | 11.48% |
2017 Q1 | 161.65 Million TWD | 4.27% |
2017 FY | 692.82 Million TWD | 14.84% |
2017 Q4 | 180.21 Million TWD | 0.0% |
2017 Q2 | 161.65 Million TWD | 0.0% |
2016 Q1 | 146.45 Million TWD | 9.62% |
2016 Q2 | 146.45 Million TWD | 0.0% |
2016 Q3 | 155.02 Million TWD | 5.86% |
2016 FY | 603.3 Million TWD | 13.26% |
2016 Q4 | 155.02 Million TWD | 0.0% |
2015 Q4 | 133.6 Million TWD | 0.0% |
2015 Q2 | 122.81 Million TWD | 0.0% |
2015 Q3 | 133.6 Million TWD | 8.79% |
2015 Q1 | 122.81 Million TWD | 17.1% |
2015 FY | 532.69 Million TWD | 39.06% |
2014 Q2 | 80.75 Million TWD | 0.0% |
2014 Q3 | 104.87 Million TWD | 29.87% |
2014 FY | 383.07 Million TWD | 35.42% |
2014 Q4 | 104.87 Million TWD | 0.0% |
2014 Q1 | 80.75 Million TWD | 20.21% |
2013 Q2 | 65.21 Million TWD | 0.0% |
2013 Q4 | 67.17 Million TWD | 0.0% |
2013 Q1 | 65.21 Million TWD | 0.0% |
2013 FY | 282.88 Million TWD | 98.86% |
2013 Q3 | 67.17 Million TWD | 3.0% |
2012 FY | 142.25 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 495.65 Million TWD | -240.395% |
Maxigen Biotech Inc. | 274.24 Million TWD | -515.209% |
SciVision Biotech Inc. | 312.85 Million TWD | -439.281% |
Bionime Corporation | 673.63 Million TWD | -150.458% |
Visco Vision Inc. | 522.44 Million TWD | -222.935% |